PRAXHIGH SIGNALFINANCIAL10-K

PRAX nearly doubled its balance sheet size with stockholders' equity growing 97% to $878M, but R&D expenses surged 75% and operating cash burn worsened dramatically from -$132M to -$249M.

The massive balance sheet expansion suggests a significant equity raise that provided substantial new capital, but the company is burning through cash at an accelerated rate with operating losses deepening 63%. The increased share count from 20.2M to 27.9M shares confirms dilutive equity financing, while the doubling of current liabilities indicates growing operational obligations that investors should monitor closely.

Comparing 2026-02-19 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

PRAX experienced dramatic growth across all balance sheet metrics with total assets nearly doubling to $938M and cash increasing 66% to $357M, indicating a major capital raise during the period. However, the company's cash burn accelerated significantly with operating cash flow deteriorating 89% to -$249M and R&D expenses surging 75% to $267M, reflecting aggressive investment in their CNS pipeline. While the capital infusion provides runway, the accelerating burn rate and 38% share count increase signal meaningful dilution for existing shareholders, creating a mixed picture of expanded resources but intensifying operational cash demands.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+97.1%
$445.4M$878.1M

Equity base grew 97.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+94.1%
$483.1M$937.9M

Asset base grew 94.1% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
-89%
-$131.8M-$249.1M

Operating cash flow fell 89% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+75.3%
$152.4M$267.1M

R&D investment increased 75.3% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-65.9%
-$182.8M-$303.3M

Net income declined 65.9% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
+65.9%
$215.4M$357.3M

Cash position surged 65.9% — strong cash generation or capital raise providing significant financial cushion.

Operating Income
P&L
-63%
-$200.2M-$326.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Liabilities
Balance Sheet
+59.2%
$37.5M$59.8M

Current liabilities surged 59.2% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+58.7%
$37.7M$59.8M

Liabilities grew 58.7% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Assets
Balance Sheet
+51.1%
$404.4M$610.9M

Current assets grew 51.1% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-19
PRIOR — 2025-02-28
ADDED
As of February 16, 2026, the registrant had 27,850,833 shares of common stock, $0.0001 par value per share, outstanding.
Management's Discussion and Analysis of Financial Condition and results of Operations 88 Item 7A.
You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed with the Securities and Exchange Commission as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.
Business BUSINESS COMPANY OVERVIEW We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.
To date, Cerebrum has generated three clinical stage product candidates, ulixacaltamide, vormatrigine and relutrigine, as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
+7 more — sign up free →
REMOVED
As of February 26, 2025, the registrant had 20,163,250 shares of common stock, $0.0001 par value per share, outstanding.
Management's Discussion and Analysis of Financial Condition and results of Operations 86 Item 7A.
We anticipate that we will continue to incur significant losses for the foreseeable future.
If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements.
Business BUSINESS COMPANY OVERVIEW We are a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →